Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Calculus Vct Plc LSE:CLC London Ordinary Share GB00BYQPF348 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 50.00 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
45.00 55.00 50.00 50.00 50.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.08 -0.28 -0.70 15
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 50.00 GBX

Calculus Vct (CLC) Latest News

More Calculus Vct News
Calculus Vct Investors    Calculus Vct Takeover Rumours

Calculus Vct (CLC) Discussions and Chat

Calculus Vct (CLC) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Calculus Vct trades in real-time

Calculus Vct (CLC) Top Chat Posts

Top Posts
Posted at 04/2/2023 08:20 by Calculus Vct Daily Update
Calculus Vct Plc is listed in the Equity Investment Instruments sector of the London Stock Exchange with ticker CLC. The last closing price for Calculus Vct was 50p.
Calculus Vct Plc has a 4 week average price of 0p and a 12 week average price of 50p.
The 1 year high share price is 65p while the 1 year low share price is currently 50p.
There are currently 30,513,975 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Calculus Vct Plc is £15,256,987.50.
Posted at 12/10/2010 06:33 by 22hoper
The Hydra Management part of the company is generating good cash and with new contracts things are looking up for clc.
Posted at 30/10/2007 16:19 by orange1
powwow
Worrying about why a share you don't own has gone from 50p to 3p... happy days.
I have held from 170p and am definitely "at odds" as to why it went from 170 to 3p. Luckily I have never held any other share so it has been enabled me to concentrate on this one.
LOL!

Posted at 09/10/2007 10:12 by lionelh
I've been in this share for five or six years now since I saw a buy recommendation in Techinvest. In that time it has lost over 90% of its value (I can remember when it was nearly 50p per share). My exposure to it has been small so I held on. For the first time I am seriously considering topping-up and averaging down. Continued improving newsflow can only start to move the share price ahead for a revaluation soon. It appears to be sticking a bit like ULT where continuing positive newsflow, including large NHS interest, over a period of time has failed to be recognised by the market. Cancellation of official listing should be a large saving but may lose instittional investors. I presume it will be an AIM listing instead. Good luck all patient investors.
Posted at 12/9/2007 09:05 by readbetweenthelines
I would suggest getting in on the ground level here and holding this for the coming year with the new contracts due : "It said it looks forward to reporting continued progress in the year ahead as nine clinical vision implementations will go live in 2007 "


LONDON (Thomson Financial) - Clinical Computing PLC said full-year pretax
loss narrowed by 39.6 pct and revenues increased by 7.6 pct, attributable to the restructuring programme initiated in the second half of 2005, adding it looksforward to improved results in the year ahead.
The company, which develops computer systems for the healthcare sector,
posted pretax loss of 964,638 stg from last year's 1.54 mln stg, while revenues
stood at 1.78 mln stg against 1.65 mln stg.
It said it looks forward to reporting continued progress in the year ahead
as nine clinical vision implementations will go live in 2007.
It said its restructuring programme is well underway with a new office
opened in Ipswich, providing a base to concentrate on expanding product
portfolio and delivering against the product roadmap.

Reasons to buy at current level

We`re priced at dilution levels , the chairman holds over 10% at double the level of todays stock price .Over 50% held tightly by directors and the recent RNS:29/06/2007


LONDON (Thomson Financial) - Clinical Computing PLC said it expects growth
in revenue for the first half compared with the same period last year despite a
weak US dollar, adding that it remains confident about its prospects.
At its AGM, the developer of computer systems for the healthcare sector said it has seen its US and Australian operations generating cash during the first half.
The group added that it is now working to implement its eight active
Clinical Vision flagship products, with a future revenue opportunity above 1 mln
stg.

All of this and only a £1 million market cap , the market makers have priced this one incorrect .

Buy

Posted at 01/7/2007 10:28 by rolfe and nolan
I expect to see CLC trading in double figures this coming week. CLC will now bear the fruit of it's labours.
Posted at 29/6/2007 12:01 by orange1
Well, I never ....
We've only gone out and won ourselves another contract! Let the mad buying frenzy begin.

Today's AGM Statement in full:

"Since the Company began its restructuring plan in the first half of 2005 the
Group has reported steady progress with its operations and improving financial
performance with losses decreasing steadily over each of the subsequent
reporting periods. The following trading areas were noted by Howard Kitchner,
Chairman:

* The Company is expecting to report comparative period on period
improvements to top line revenues for the six month period to 30 June 2007. This
is in spite of the significant weakening of the US dollar, over the comparative
periods.

* During the first half of 2007 the Company has seen its US and
Australian operations generating cash. At the present time the Company continues
to fund its UK operations with debt.

* Since the announcement of our 2006 final results on 27 April 2007, the
Group has won a contract in the US to support the renal service department of a
hospital with CLINIICAL VISION. Additionally, two customers have completed the
implementation of CLINCIAL VISION.

* The Group is now working through eight active CLINICAL VISION
implementations, with a future revenue opportunity of over #1,000,000.

* With respect to the UK market, the Company continues to build
partnerships and work with our UK customer base on an upgrade programme from
PROTON to CLINICAL VISION.

With these trading conditions in mind the Board remains confident about the
Group's prospects and continues to view the future with optimism."

P.S. What good typists they have over at CLC: is the flagship product called CLINIICAL VISION or CLINCIAL VISION?

Posted at 22/6/2007 15:46 by bracke
"Any reason for such a low NMS?"

To stop selling of a large number at the bid price without a requote?

Posted at 22/6/2007 14:15 by cyberpost
so this is the share you were secretly emailing 'knowing' about ?
Posted at 29/11/2006 13:18 by orange1
The chairman of CLC has been a big buyer of the shares of late together with a "connected person" substantial shareholder David Altschuler.
The chairman Howard Kitchner is a Chartered Accountant who has worked in merchant banking, investment banking and the leasing industry. He is currently chairman of National Leasing & Finance Co. David Altschuler is also a chartered accountant and also at National Leasing & Finance Co.

Back in the early 90s the two of them had a brief career as film producers (Leon the Pig Farmer with walk on parts to boot).
http://movies.yahoo.com/movie/1800202453/info

If I were one of ADVFN's more notorious rampers I would be suggesting that this can only mean one thing: that United Pictures or Time Warner (pick your film producer of choice) are about to reverse into CLC and that now is the time to fill your boots before the rest of the world catches on.

LOL!

Posted at 23/3/2006 10:16 by orange1
Bakunin
Welcome! I can't quite believe that somebody is actually interested in this minnow.

The £1.25m annual revenue in maintenance fees which I have previously mentioned is based on the figure in the notes to the most recent annual accounts £1.1m
uplifted so as to reflect the new contracts. CLC have a large stable customer base who pay maintenance fees every year. Not all of these were originally sold CLC products. A chunk of these customers were acquired in the 90s when CLC acquired them from Fresenius (from memory).

I agree that it is unlikely that these are paying 17.5% of the licence fee. It is probably a much lower percentage. But for those acquiring CV4 a rate of 15 to 17.5% is not unreasonable I believe.

The CV4 licence fees are higher than 50k but, as you say, there have not been many.

It has always been the case with CLC that a spate of licences sold would transform the fortunes of the company. Just £1m to £2m of licences sold in one year woulld have done the trick. But sadly this has never come to pass.
Based on the figures last September, the company's financial situation and prospects did not seem to warrant the rock bottom rating we have today.
But there has been no news since then and the price today tells its own sad story.

I still hold but much more in hope than expectation. The upcoming results should tell us more.

Calculus Vct share price data is direct from the London Stock Exchange
Your Recent History
LSE
CLC
Calculus V..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230205 04:55:18